Launxp Biomedical Co

Launxp Biomedical Co Stock-Based Compensation

The Stock-Based Compensation (SBC) of Launxp Biomedical Co (6876.TWO) as of Oct 17, 2026 is 4.71 M TWD. In the previous year, Stock-Based Compensation (SBC) was 5.28 M TWD — a change of -10.82% (lower).

Stock-Based Compensation

4.71 MTWD

YoY

-10.82%

Last updated:

Stock-Based Compensation (SBC) of Launxp Biomedical Co is 2024 4.71 M TWD. Stock-Based Compensation (SBC) of Launxp Biomedical Co was 2023 5.28 M TWD. It decreases by -10.82% lower compared to the previous year.

The Launxp Biomedical Co Stock-Based Compensation history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Stock-Based Compensation
Date
Stock-Based Compensation
Jan 1, 2021
0.00 TWD
Jan 1, 2022
600,000.00 TWD
Jan 1, 2023
5.28 M TWD
Jan 1, 2024
4.71 M TWD
The Launxp Biomedical Co Stock-Based Compensation history
YEARStock-Based CompensationYoY
4.71 MTWD-10.82%
5.28 MTWD+779.50%
600,000.00TWD—
0.00TWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Launxp Biomedical Co Stock analysis

What does Launxp Biomedical Co do? Launxp Biomedical Co Ltd, headquartered in Taichung, Taiwan, is a biotechnology company focused on developing innovative cancer therapeutics. Listed on 18 January 2024, the company specializes in novel drug development, particularly targeting acute myeloid leukemia (AML) and other oncological conditions. Its pipeline includes LXPA1788, a multi-target kinase inhibitor; LXPA1988, a novel chemical structure drug targeting FLT3 mutations; and several other compounds with new indications and dosage forms for cancer treatment. Launxp Biomedical Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Launxp Biomedical Co stock

Stock-Based Compensation (SBC) of Launxp Biomedical Co is 4.71 M TWD in 2024.

Stock-Based Compensation (SBC) of Launxp Biomedical Co changed from 5.28 M TWD to 4.71 M TWD, representing a -10.82% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Stock-Based Compensation (SBC) Launxp Biomedical Co since 2006 – with annual values, charts, and detailed analysis.

Stock-based compensation is a non-cash expense representing equity awards to employees. High SBC can dilute existing shareholders and inflate reported cash flow.

Stock-Based Compensation (SBC)'s TWD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Stock-Based Compensation (SBC)'s Launxp Biomedical Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Cash Flow — Launxp Biomedical Co

Operating Cash FlowCapital ExpendituresFree Cash FlowFCF per ShareDividends PaidShare BuybacksInvesting Cash FlowFinancing Cash FlowCapEx / RevenueCash Flow per ShareStock-Based CompensationChange in Working CapitalAcquisitions (Net)Net Change in CashCapEx/OCFFCF/Net IncomeFCF ConversionCash ConversionTotal Shareholder PayoutCapEx/D&A

All Key Metrics — Launxp Biomedical Co